HCW Biologics (HCWB) Competitors

Ovid Therapeutics (NASDAQ:OVID) and HCW Biologics (NASDAQ:HCWB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

Do institutionals & insiders have more ownership in OVID or HCWB?

72.2% of Ovid Therapeutics shares are owned by institutional investors. Comparatively, 3.0% of HCW Biologics shares are owned by institutional investors. 13.1% of Ovid Therapeutics shares are owned by company insiders. Comparatively, 42.7% of HCW Biologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Does the media prefer OVID or HCWB?

In the previous week, Ovid Therapeutics had 2 more articles in the media than HCW Biologics. MarketBeat recorded 3 mentions for Ovid Therapeutics and 1 mentions for HCW Biologics. HCW Biologics' average media sentiment score of 1.87 beat Ovid Therapeutics' score of 0.92 indicating that HCW Biologics is being referred to more favorably in the news media.

Company	Overall Sentiment
Ovid Therapeutics	Positive
HCW Biologics	Very Positive

Is OVID or HCWB more profitable?

HCW Biologics has a net margin of -1,712.94% compared to Ovid Therapeutics' net margin of -4,562.23%. HCW Biologics' return on equity of 0.00% beat Ovid Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-4,562.23%	-34.17%	-25.34%
HCW Biologics	-1,712.94%	N/A	-90.09%

Which has preferable valuation & earnings, OVID or HCWB?

Ovid Therapeutics has higher earnings, but lower revenue than HCW Biologics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$570K	49.52	-$26.43M	-$0.35	-1.13
HCW Biologics	$1.45M	4.30	-$30.02M	-$23.25	-0.19

Do analysts rate OVID or HCWB?

Ovid Therapeutics presently has a consensus target price of $3.13, suggesting a potential upside of 687.35%. HCW Biologics has a consensus target price of $35.00, suggesting a potential upside of 710.19%. Given HCW Biologics' higher possible upside, analysts plainly believe HCW Biologics is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20
HCW Biologics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk & volatility, OVID or HCWB?

Ovid Therapeutics has a beta of 0.13, suggesting that its stock price is 87% less volatile than the S&P 500. Comparatively, HCW Biologics has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500.

Summary

Ovid Therapeutics beats HCW Biologics on 9 of the 17 factors compared between the two stocks.